<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">The results of this study were consistent with what was observed in previous phase I trials and a recently conducted phase IIb trial in the field carried out in the Netherlands
 <sup>
  <xref ref-type="bibr" rid="CR38">38</xref>
 </sup>. In this 175-participant study, one dose of adjuvanted FLU-v was shown to be safe and to induce long-lasting cell-mediated immune responses.
</p>
